Search

Displaying results 1581 - 1590 of 10000 in total
  1. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.

  2. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.

    Categories: Receptors, Prostaglandin E, EP2 Subtype, agonistsSynonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate
  3. Drug

    Acetylcarnitine

    go.drugbank.com/drugs/DB08842
    ApprovedInvestigational

    Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. … Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India

  4. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant]. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

  5. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution … Dihydroergotamine is used as an abortive therapy for migraines.

    Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
  6. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections. … [A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].

  7. Drug

    Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14407
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze
  8. Drug

    Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14559
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze
  9. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.

  10. Target

    Cyclin-dependent kinase 9

    go.drugbank.com/bio_entities/BE0002207
    TargetHumans

    This complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed … The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351).

    Synonyms: Tat-associated kinase complex catalytic subunit